ZA201206254B - Novel salts for the manufacture of pharmaceutical compositions - Google Patents

Novel salts for the manufacture of pharmaceutical compositions

Info

Publication number
ZA201206254B
ZA201206254B ZA2012/06254A ZA201206254A ZA201206254B ZA 201206254 B ZA201206254 B ZA 201206254B ZA 2012/06254 A ZA2012/06254 A ZA 2012/06254A ZA 201206254 A ZA201206254 A ZA 201206254A ZA 201206254 B ZA201206254 B ZA 201206254B
Authority
ZA
South Africa
Prior art keywords
manufacture
pharmaceutical compositions
novel salts
salts
novel
Prior art date
Application number
ZA2012/06254A
Inventor
Imre Kiraly
Peter Trinka
Balazs Volk
Laszlo Pongo
Jozsef Barkocyz
Peter Slegel
Magdolna Obreczan
Andras Dancso
Monika Mezovari
Tibor Sazabo
Gyorgy Ruzsics
Laszlo Szlavik
Gyula Lukacs
Andras Boza
Original Assignee
Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HU1000069A priority Critical patent/HU1000069A2/en
Priority to PCT/HU2011/000014 priority patent/WO2011110876A1/en
Application filed by Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag filed Critical Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag
Publication of ZA201206254B publication Critical patent/ZA201206254B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
ZA2012/06254A 2010-02-02 2012-08-20 Novel salts for the manufacture of pharmaceutical compositions ZA201206254B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
HU1000069A HU1000069A2 (en) 2010-02-02 2010-02-02 New salts for the preparation of pharmaceutical composition
PCT/HU2011/000014 WO2011110876A1 (en) 2010-02-02 2011-02-02 Novel salts for the manufacture of pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ZA201206254B true ZA201206254B (en) 2013-10-30

Family

ID=42113180

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/06254A ZA201206254B (en) 2010-02-02 2012-08-20 Novel salts for the manufacture of pharmaceutical compositions

Country Status (5)

Country Link
CN (1) CN102858762A (en)
EA (1) EA022496B1 (en)
HU (1) HU1000069A2 (en)
WO (1) WO2011110876A1 (en)
ZA (1) ZA201206254B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
WO2012027543A1 (en) * 2010-08-25 2012-03-01 Teva Pharmaceuticals Usa, Inc. Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof
WO2012077136A2 (en) * 2010-12-06 2012-06-14 Msn Laboratories Limited Process for the preparation of benzimidazole derivatives and its salts
CN102558153A (en) * 2012-02-08 2012-07-11 北京阜康仁生物制药科技有限公司 Novel pharmaceutical salt of dabigatran etexilate and preparation method thereof
EP2631234A1 (en) 2012-02-23 2013-08-28 Esteve Química, S.A. Solid forms of dabigatran etexilate mesylate and processes for their preparation
WO2013144971A1 (en) * 2012-03-27 2013-10-03 Cadila Healthcare Limited New solid forms of dabigatran etexilate bisulfate and mesylate and processes to prepare them
CN102633777B (en) * 2012-03-31 2014-04-16 天津药物研究院 Dabigatran etexilate 2-ketoglutarate as well as preparation method and application thereof
US9273030B2 (en) 2012-04-02 2016-03-01 Msn Laboratories Private Limited Process for the preparation of benzimidazole derivatives and salts thereof
CN103539779B (en) * 2012-07-13 2016-12-21 四川海思科制药有限公司 A kind of hydroxyl-substituted sulfonate of dabigatran etcxilate and its production and use
EP2872499A1 (en) * 2012-07-16 2015-05-20 Interquim, S.A. Process for the preparation of intermediates for the synthesis of dabigatran etexilate, and crystalline forms of said intermediates
IN2015DN02601A (en) 2012-09-28 2015-09-18 Ranbaxy Lab Ltd
IN2015DN02616A (en) 2012-09-28 2015-09-18 Ranbaxy Lab Ltd
CN103864756B (en) * 2012-12-11 2018-06-15 四川海思科制药有限公司 Fourth disulfonic acid dabigatran etcxilate and its preparation method and application
WO2014178017A1 (en) 2013-04-30 2014-11-06 Ranbaxy Laboratories Limited Dabigatran etexilate impurity, process of its preparation, and its use as a reference standard
EP2835370A1 (en) 2013-08-08 2015-02-11 Medichem, S.A. New crystals of dabigatran etexilate mesylate
CN104418840A (en) * 2013-09-05 2015-03-18 天津汉瑞药业有限公司 Dabigatran etexilate mesylate anhydrous compound
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CN104892574A (en) 2014-03-04 2015-09-09 浙江海正药业股份有限公司 Dabigatran etexilate mesylate crystal forms, preparation methods and uses thereof
CN104974137A (en) * 2014-04-04 2015-10-14 江苏天士力帝益药业有限公司 New crystal forms of dabigatran etexilate mesylate and preparation method thereof
EP3169677A1 (en) * 2014-07-18 2017-05-24 OLON S.p.A. Crystalline compounds of dabigatran etexilate
CN105348260A (en) * 2014-08-19 2016-02-24 天津药物研究院 Dabigatran etexilate hydrobromide, preparation method and applications thereof
CN106554370A (en) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 Dabigatran derivant containing phosphate ester and its production and use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE121699A1 (en) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Disubstituted bicyclic heterocycles as inhibitors of thrombin
DE10337697A1 (en) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablet containing 3 - [(2 - {[4- (hexyloxycarbonylamino-iminomethyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] - propionic acid ethyl ester or its salts
DE10339862A1 (en) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg New crystalline forms of ethyl 3-(N-(2-(4-(hexyloxycarbonylamidino)phenylaminomethyl)-1-methyl-1H-benzimidazole-5-carbonyl)-N-(2-pyridyl)amino)propionate methanesulfonate used for post-operative prophylaxis of deep vein thrombosis
DE102005020002A1 (en) * 2005-04-27 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg New hexyloxycarbonylamino-imino-methyl-phenylamino-methyl-benzimidazole-pyridine-propionic acid-ethyl ester salts such as hydrochloride useful for the prophylaxis of vein thrombosis and stroke
DE102005025728A1 (en) 2005-06-04 2006-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Polymorphs of 3 - [(2 - {[4- (hexyloxycarbonylamino-imino-methyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] -propionic acid ethyl ester
DE102005061623A1 (en) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Improved process for the preparation of 4- (benzimidazolylmethylamino) -benzamidines and their salts
CL2007002068A1 (en) * 2006-07-17 2008-01-18 Boehringer Ingelheim Int Use of dabigatran, dabigatran etexilate, (n-2-pyridyl-N-2-ethoxycarbonylethyl) amide the acid 1-methyl-2- [4- (n-hydroxyamidino) fenilaminoetil] benzimidazol-5-yl-carboxylic acid, melagatran, ximelagatran, hirudin, hirulog and argatroban for the treatment of stroke, myocardial infarction, thrombosis, pulmonary embolism, among others.
US20100087488A1 (en) * 2006-10-10 2010-04-08 Boehringer Ingelheim International Gmgh Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
DE102006054005A1 (en) 2006-11-16 2008-05-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg New polymorphs of 3 - [(2 - {[4- (hexyloxycarbonylamino-imino-methyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] -propionic acid ethyl
CN100556642C (en) * 2007-06-06 2009-11-04 中国科学院化学研究所 The regulate and control method of aliphatic poly adipic acid fourth diester material degradation performance

Also Published As

Publication number Publication date
WO2011110876A8 (en) 2012-07-05
HU1000069D0 (en) 2010-04-28
WO2011110876A1 (en) 2011-09-15
CN102858762A (en) 2013-01-02
EA201290726A1 (en) 2013-07-30
EA022496B1 (en) 2016-01-29
HU1000069A2 (en) 2012-05-02

Similar Documents

Publication Publication Date Title
HRP20181658T1 (en) Solid compositions
HK1243746A1 (en) Compositions
ZA201703992B (en) Inhalable pharmaceutical compositions
IL276012D0 (en) Pharmaceutical compositions comprising sorbitan esters
HRP20191555T1 (en) Pharmaceutical composition
IL233216D0 (en) Oral care compositions
HK1183802A1 (en) Therapeutic oral composition
HK1209638A1 (en) Pharmaceutical compositions
ZA201308086B (en) Derivatives of 1-anino-2-cyclopropylboronic acid
HK1201212A1 (en) Hemostatic compositions
EP2758441A4 (en) Modified polyethylene compositions
ZA201207093B (en) Solid compositions
ZA201301329B (en) Novel compounds and compositions for the inhibition of nampt
IL231414A (en) Compositions for the preparation of imaging agents
ZA201208336B (en) Controlled release pharmaceutical compositions of tapentadol
HRP20160374T1 (en) Pharmaceutical compounds
DK3284467T3 (en) Nicotine-containing pharmaceutical compositions
PT2566930T (en) Use of compositions for refrigeration
EP2568975A4 (en) Film compositions for delivery of actives
EP2527400A4 (en) Polylactic acid composition
RU2018115685A (en) Pharmaceutical composition
PL2598165T3 (en) Immunogenic anti-inflammatory compositions
IL230010A (en) Inhalable pharmaceutical compositions
SG11201401056SA (en) Oral care compositions
IL245326D0 (en) Pharmaceutical composition